Abstract
Cumulative recent evidence from clinical trials, observational studies and case reports has shown that subcutaneous administration of immunoglobulin (SCIg) exerts similar immunomodulatory capacity than intravenous immunoglobulin (IVIg) in autoimmune neurological diseases. Besides the beneficial clinical effects, the profile of safety and autonomy for the patient is higher for SCIg, while it is cost-saving in terms of the health resources used. However, there are still very few approved indications for SCIg and a certain resistance to choose SCIg for other autoimmune conditions even despite patients’ interests. Here we present an updated review of the known immunomodulatory mechanisms of action of Ig and the current hypothesis supporting the clinical and immunological advantages of SCIg over IVIg that derive from their specific pharmacokinetic features.
Keywords: Subcutaneous immunoglobulin, immunomodulation, mechanisms of action.
Current Pharmaceutical Design
Title:Subcutaneous Immunoglobulins: A Promising Alternative for Immunomodulation?
Volume: 22 Issue: 41
Author(s): Silvia Sanchez-Ramon, Angel L. Corbi, Agueda Garcia Fidalgo and Angeles Dominguez-Soto
Affiliation:
Keywords: Subcutaneous immunoglobulin, immunomodulation, mechanisms of action.
Abstract: Cumulative recent evidence from clinical trials, observational studies and case reports has shown that subcutaneous administration of immunoglobulin (SCIg) exerts similar immunomodulatory capacity than intravenous immunoglobulin (IVIg) in autoimmune neurological diseases. Besides the beneficial clinical effects, the profile of safety and autonomy for the patient is higher for SCIg, while it is cost-saving in terms of the health resources used. However, there are still very few approved indications for SCIg and a certain resistance to choose SCIg for other autoimmune conditions even despite patients’ interests. Here we present an updated review of the known immunomodulatory mechanisms of action of Ig and the current hypothesis supporting the clinical and immunological advantages of SCIg over IVIg that derive from their specific pharmacokinetic features.
Export Options
About this article
Cite this article as:
Sanchez-Ramon Silvia, Corbi L. Angel, Fidalgo Garcia Agueda and Dominguez-Soto Angeles, Subcutaneous Immunoglobulins: A Promising Alternative for Immunomodulation?, Current Pharmaceutical Design 2016; 22 (41) . https://dx.doi.org/10.2174/1381612822666160831103806
DOI https://dx.doi.org/10.2174/1381612822666160831103806 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Brain Targeted Drug Delivery: Factors, Approaches and Patents
Recent Patents on Nanomedicine Sympathetic Nervous System Dysfunction in Multiple Sclerosis, Linking Neurodegeneration to a Reduced Response to Therapy
Current Pharmaceutical Design “SLY AS A FOXO”: New Paths with Forkhead Signaling in the Brain
Current Neurovascular Research Mechanisms of Control of Neuron Survival by the Endocannabinoid System
Current Pharmaceutical Design The Role of Tec Family Kinases in Inflammatory Processes
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry CTLA-4Ig: Uses and Future Directions
Recent Patents on Inflammation & Allergy Drug Discovery Vitamin D in Acute Kidney Injury
Inflammation & Allergy - Drug Targets (Discontinued) Stem Cell-Based Immunomodulation in Type 1 Diabetes: Beyond the Regenerative Approach
Current Pharmaceutical Design Use of Systemic Proteasome Inhibition as an Immune-Modulating Agent in Disease
Endocrine, Metabolic & Immune Disorders - Drug Targets Functional Interactions Between B Lymphocytes and the Innate Immune System
Infectious Disorders - Drug Targets Microglial Integrity is Maintained by Erythropoietin Through Integration of Akt and Its Substrates of lycogen Synthase Kinase-3β, β-Catenin, and Nuclear Factor-κB
Current Neurovascular Research Recent Advances in the Treatment of Amyotrophic Lateral Sclerosis. Emphasis on Kynurenine Pathway Inhibitors
Central Nervous System Agents in Medicinal Chemistry Leukocyte Traffic Blockade as a Therapeutic Strategy in Inflammatory Bowel Disease
Current Drug Targets NAD Metabolism and Functions: A Common Therapeutic Target for Neoplastic, Metabolic and Neurodegenerative Diseases
Current Topics in Medicinal Chemistry Detection and Transport Mechanisms of Circulating microRNAs in Neurological, Cardiac and Kidney Diseases
Current Medicinal Chemistry Inflammatory Events Following Subarachnoid Hemorrhage (SAH)
Current Neuropharmacology Biochemical Markers of Autoimmune Diseases of the Nervous System
Current Pharmaceutical Design Anti-NMDA Receptor Encephalitis in Psychiatry
Current Psychiatry Reviews Advances in Drug Delivery from Nose to Brain: An Overview
Current Drug Therapy Functions of S100 Proteins
Current Molecular Medicine